Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

PATENTS

Patents benefit patients and patent reform would spur diagnostic and therapeutic development

Nature Biotechnology volume 40, pages 1178–1180 (2022)Cite this article

Subjects

Patients need the patent system to spur the investment necessary for the continued development of life-saving diagnostics and therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Diamond v. Chakrabarty, 447 U.S. 303 (1980).

  2. Pub L. 96–517, December 12, 1980, codified in 35 U.S.C. §§ 200–12 and implemented by 37 C.F.R. § 401.

  3. Personal communication with executives of a prominent pharmaceutical company, c. 1985.

  4. Parke-Davis & Company v. H.K. Mulford Co., 196 F. 496 (2d Cir. 1912).

  5. Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156 (4th Cir. 1958).

  6. In re Bergstrom, 427 F.2d 1394 (CCPA 1970).

  7. In re Kratz, 592 F.2d 1169 (CCPA 1979).

  8. Mayo Collaborative Services v. Prometheus Labs., Inc. 566 U.S. 66 (2012).

  9. Association for Molecular Pathology v. Myriad Genetics Inc., 569 U.S. 576 (2013).

  10. Funk Bros. Seed v. Kalo Inoculant, 333 U.S. 127 (1948).

  11. Cuno Engineering Corp. v. Automatic Devices Corp., 314 U.S. 84 (1941).

  12. 35 U.S.C. §103.

  13. P.L. 82-593, 35 U.S.C.–Patents Senate report no. 82-1979, 27 June 1952, and House report no. 82-1923, 12 May 1952, comments re Section 103.

  14. Hershey, A. D. & Chase, M. J. Gen. Physiol. 36, 39–56 (1952).

    Article  CAS  Google Scholar 

  15. Berk, A. J. & Sharp, P. A. Cell 12, 721–732 (1977).

    Article  CAS  Google Scholar 

  16. Maston, G. A., Evans, S. K. & Green, M. R. Annu. Rev. Genomics Hum. Genet. 7, 29–59 (2006).

    Article  CAS  Google Scholar 

  17. Coffin, J. M. & Fan, H. Annu. Rev. Virol. 3, 29–51 (2016).

    Article  CAS  Google Scholar 

  18. Association of University Technology Managers (AUTM). AUTM’s comments on USPTO’s Patent Eligibility Jurisprudence Study (Docket No. PTO-P-2021-0032) (14 October 2021); https://autm.net/AUTM/media/About-Tech-Transfer/Documents/AUTMs-Comments-on-USPTOs-Patent-Eligibility-Jurisprudence-Study-Docket-Number-PTO-P-2021–0032.pdf

  19. Taylor, D. O. Cardozo Law Rev. 41, 2019–2116 (2020).

    Google Scholar 

  20. Madigan, K. & Mossoff, A. Geo. Mason Law Rev. 24, 939–960 (2017).

    Google Scholar 

  21. German Center for Disease Research (DZIF). Researchers develop first diagnostic test for novel coronavirus in China [press release] (16 January 2020); https://www.dzif.de/en/researchers-develop-first-diagnostic-test-novel-coronavirus-china

  22. US Patent Office (USPTO). 2014 Interim Eligibility Guidance Examples; https://www.uspto.gov/sites/default/files/documents/101_examples_1to36.pdf (2014).

  23. USPTO. 2019 Revised Patent Subject Matter Eligibility Guidance; https://www.uspto.gov/sites/default/files/documents/101_examples_37to42_20190107.pdf (2019)

  24. USPTO. Appendix 1 to the October 2019 Update: Subject Matter Eligibility Life Sciences & Data Processing Examples; https://www.uspto.gov/sites/default/files/documents/peg_oct_2019_app1.pdf (2019)

Download references

Acknowledgements

This material was presented at the NAS/CSTL panel Patent Protections for Genetic Products and Processes after AMP v. Myriad (22–23 March 2022). The opinions expressed herein are those of the author alone and do not necessarily represent the views of the author’s current or former employers. The author was a member of the legal team representing Myriad Genetics in AMP v. Myriad.

Author information

Authors and Affiliations

  1. Intellectual Property Department, REGENXBIO Inc., New York, NY, USA

    Laura A. Coruzzi

Authors
  1. Laura A. Coruzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura A. Coruzzi.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coruzzi, L.A. Patents benefit patients and patent reform would spur diagnostic and therapeutic development. Nat Biotechnol 40, 1178–1180 (2022). https://doi.org/10.1038/s41587-022-01405-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-022-01405-z

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research